Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23675265 | 0.85 | GRM5 (0.48) | GRM5LRRK2HPGDGAAEP300 | |
| SCHEMBL29564740 | 0.85 | GRM5 (0.48) | GRM5LRRK2HPGDGAAEP300 | |
| SCHEMBL24929599 | 0.85 | GRM5 (0.50) | GRM5LRRK2HPGD | |
| SCHEMBL24329653 | 0.79 | GRM5 (0.42) | GRM5LRRK2HPGD | |
| SCHEMBL28883069 | 0.75 | CRBN (0.54) | ALDH1A1HPGDCYP2D6TSHRUSP2 | |
| SCHEMBL24929270 | 0.75 | LRRK2 (0.45) | ALDH1A1KMT2ALRRK2HPGDGAA | |
| SCHEMBL23680626 | 0.74 | GRM5 (0.46) | GRM5ALDH1A1LRRK2HPGD | |
| SCHEMBL25300159 | 0.74 | GRM5 (0.60) | GRM5LRRK2HPGDTSHRUSP2 | |
| SCHEMBL30589648 | 0.74 | GRM5 (0.60) | GRM5LRRK2HPGDTSHRUSP2 | |
| SCHEMBL23675258 | 0.72 | GRM5 (0.41) | GRM5ALDH1A1LRRK2HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374579-A1 | BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO INC. | 2024-11-14 | — | — | US | disclosed |
| EP-4377314-A1 | BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING | Epirium Bio Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023009618-A1 | BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023009618-A1 | BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374579-A1 | BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, GCDH | GRM5 1582/4885ALDH1A1 224/4885KMT2A 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.